ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on anaphylaxis prevention, will host a conference call and webcast to discuss its Q2 2025 financial results on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.
Participants can register for the event to receive dial-in information. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days after the event.
ARS Pharmaceuticals (Nasdaq: SPRY), un'azienda biofarmaceutica specializzata nella prevenzione dell'anafilassi, terrà una conference call e una webcast per discutere i suoi risultati finanziari del secondo trimestre 2025 mercoledì 13 agosto 2025 alle 5:30 a.m. PT / 8:30 a.m. ET.
I partecipanti possono registrarsi all'evento per ricevere le informazioni per la chiamata. La webcast e le slide della presentazione saranno disponibili nella pagina Eventi e Presentazioni del sito web aziendale, con una replica accessibile per 30 giorni dopo l'evento.
ARS Pharmaceuticals (Nasdaq: SPRY), una compañía biofarmacéutica enfocada en la prevención de la anafilaxia, realizará una llamada conferencia y una transmisión web para discutir sus resultados financieros del segundo trimestre de 2025 el miércoles 13 de agosto de 2025 a las 5:30 a.m. PT / 8:30 a.m. ET.
Los participantes pueden registrarse para el evento y recibir la información para la llamada. La transmisión web y las diapositivas de la presentación estarán disponibles en la página de Eventos y Presentaciones del sitio web de la compañía, con una repetición accesible durante 30 días después del evento.
ARS Pharmaceuticals (나스닥: SPRY)는 아나필락시스 예방에 중점을 둔 생명공학 제약회사로, 2025년 2분기 재무 실적을 논의하기 위해 2025년 8월 13일 수요일 오전 5:30 PT / 오전 8:30 ET에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
참석자는 이벤트 등록을 통해 전화 접속 정보를 받을 수 있습니다. 웹캐스트와 발표 자료는 회사 웹사이트의 이벤트 및 프레젠테이션 페이지에서 확인할 수 있으며, 이벤트 종료 후 30일간 다시보기 서비스도 제공됩니다.
ARS Pharmaceuticals (Nasdaq : SPRY), une société biopharmaceutique spécialisée dans la prévention de l'anaphylaxie, organisera une conférence téléphonique et une webdiffusion pour discuter de ses résultats financiers du deuxième trimestre 2025 le mercredi 13 août 2025 à 5h30 PT / 8h30 ET.
Les participants peuvent s'inscrire à l'événement pour recevoir les informations d'appel. La webdiffusion et les diapositives de présentation seront accessibles via la page Événements et Présentations du site web de la société, avec une rediffusion disponible pendant 30 jours après l'événement.
ARS Pharmaceuticals (Nasdaq: SPRY), ein biopharmazeutisches Unternehmen, das sich auf die Prävention von Anaphylaxie spezialisiert hat, wird am Mittwoch, den 13. August 2025, um 5:30 Uhr PT / 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um die Finanzergebnisse des zweiten Quartals 2025 zu besprechen.
Teilnehmer können sich für die Veranstaltung registrieren, um die Einwahlinformationen zu erhalten. Das Webcast und die Präsentationsfolien sind auf der Seite Events & Präsentationen der Unternehmenswebsite verfügbar, mit einer Wiedergabe für 30 Tage nach der Veranstaltung.
- None.
- None.
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Monique Allaire, THRUST
monique@thrustsc.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
FAQ
When is ARS Pharmaceuticals (SPRY) Q2 2025 earnings call?
How can I access ARS Pharmaceuticals (SPRY) Q2 2025 earnings webcast?
How long will ARS Pharmaceuticals Q2 2025 earnings webcast be available?
What does ARS Pharmaceuticals (SPRY) do?
